Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. - Wikidata - wikimedia - TriplyDB

Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.

Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.

http://www.wikidata.org/entity/Q39128691

about

Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations.Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes.Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.An Evaluation of the Stemness, Paracrine, and Tumorigenic Characteristics of Highly Expanded, Minimally Passaged Adipose-Derived Stem Cells HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.Concise reviews: cancer stem cells: from concept to cure.ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21.A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells.Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation.Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells.Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma.Snail1 expression is required for sarcomagenesis.Human acute leukemia induced pluripotent stem cells: a unique model for investigating disease development and pathogenesis.Transcription Factor C/EBP Homologous Protein in Health and Diseases.FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.Modeling mixed-lineage-rearranged leukemia initiation in CD34+ cells: a "CRISPR" solution.Soft Tissue Sarcoma Cancer Stem Cells: An Overview

P2860

Q26745742-A534F9B7-7997-4177-B571-D2C6EBE35140 Q27342050-FDEDBF7C-D71F-4FDF-B186-C5505B248130 Q28597747-F6E0D716-63F2-4396-BC82-A3EDA13E33C3 Q33649056-5D7BB92A-EDB8-41F7-B33B-BB2D9077EB0E Q33722454-3962648E-D863-43B9-AD13-36A6C907D788 Q33795203-1A3D0D2B-7B49-45B7-A65B-6F10A610C693 Q33828556-C15ABF81-2655-41C5-BC1A-4EE2C7A14395 Q36134696-4D04E688-C66C-4C7E-B875-F9627CED26A2 Q36729440-4A481A4F-3CF3-4BC2-A550-ADCE11C700AD Q38235552-256DF111-B051-4E9A-B6AB-32D21F5E3960 Q38743525-B3F807BB-C3D8-4F85-8DCD-668D7FB649FB Q38917207-ACF9AB79-71E1-4BDE-829B-304E2767DCFE Q38943709-DB000290-E06E-4EF0-A46E-015369FA30F8 Q39032517-9EDC8230-F337-4808-B9FA-EFA291D8971C Q41552416-E88E4116-7814-42D7-94D2-9721D046E043 Q41868274-431BB99A-1D98-4482-BAF2-5125AC28E52E Q42332325-A759C92C-2C82-4E4A-BF3F-25CAA6CBD52F Q47304202-9E74DD3D-8AE5-4E34-87A3-D7D1139A5B1C Q47391013-48A614D1-BB89-44F3-AF0C-4F02D66B0996 Q50196263-A34C3FBF-7C64-4E4D-933C-3C8FFA52EDC5 Q58707604-D54DAC35-7365-4BE2-88B6-8A46D992603A

P2860

Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.

http://www.wikidata.org/entity/Q39128691

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Expression of FUS-CHOP fusion ...... mixoid liposarcoma formation.

@en

Expression of FUS-CHOP fusion ...... mixoid liposarcoma formation.

@nl

type

label

Expression of FUS-CHOP fusion ...... mixoid liposarcoma formation.

@en

Expression of FUS-CHOP fusion ...... mixoid liposarcoma formation.

@nl

prefLabel

Expression of FUS-CHOP fusion ...... mixoid liposarcoma formation.

@en

Expression of FUS-CHOP fusion ...... mixoid liposarcoma formation.

@nl

P1433

Q39128691-ADB95C87-8463-473F-A959-3F3E961664CE

P1476

Q39128691-2CD192A4-EC35-4817-B909-C14A3CB710F7

P2093

Q39128691-2D54E04C-065D-4C82-B570-71DABAA7B721

Q39128691-3D42197A-3FAC-4229-B418-E90FAF463FBD

Q39128691-6DABF730-5CDF-4377-9057-2C628DBB773A

Q39128691-755F1196-6D20-4C68-8DB4-5A7739D2F838

Q39128691-855CF4B6-690F-4F5E-9960-AF03B8D15C04

Q39128691-F1A1A673-4CB9-40C8-8367-CB280D4C3A59

P2860

Q39128691-0743BF8B-AD85-4907-BC71-D8709F2046CF

Q39128691-1298D957-745C-4E82-B01B-0D564613E4DF

Q39128691-137D6E03-E5BD-4F75-AA19-7F09AFDB745F

Q39128691-199DE968-7E52-4B87-992F-102AD52C21D0

Q39128691-228E1673-BD6C-4075-9D08-BA05A5D13282

Q39128691-2971EC42-D5E1-4122-A32C-5CEE366C6873

Q39128691-2E3CEB74-EF35-40A6-842D-2D087EFE56EA

Q39128691-3336D912-C502-43DF-ADC7-F40216FAAD6E

Q39128691-3A368E3B-9B35-4872-8569-7AB294745BAD

Q39128691-3C537569-5558-4265-BD4F-B4E64758A189

P304

Q39128691-9836A3FB-4AC7-4DF0-BCCF-6CB890D16F8F

P31

Q39128691-B64B39F7-354D-4220-8E7C-619B43B2BC4F

P356

Q39128691-7279A358-17E6-4548-9B1E-694873CF27E3

P433

Q39128691-EC16A65F-22D9-47AB-9849-0BF9AF0E3897

P478

Q39128691-591647F7-9A53-4288-9F20-6305780DD601

P50

Q39128691-022DE116-E642-4973-B799-B2EEF3C31AF8

Q39128691-17192EE8-B083-4BAD-9C91-CAC65B597FC8

Q39128691-62D5DD6C-55F1-4C71-BF61-13C5959B62DE

Q39128691-9424044D-76EE-4676-AF41-DDCA2A08CDA6

Q39128691-B396C4AC-3B54-48FE-82BC-B68538802435

Q39128691-CC217E64-B0C9-42CA-B08D-04A0F7087711

P577

Q39128691-2E3D2FA3-3E5A-4214-A47B-FE72B72DA575

P5875

Q39128691-41F2A84A-B496-44ED-BA61-BB6A9E604B5E

P698

Q39128691-18FE3F87-2D85-415D-8DF2-3A8ABEC586BF

P356

P1433

P1476

Expression of FUS-CHOP fusion ...... s mixoid liposarcoma formation

@en

P2093

Andrew Williams

http://www.w3.org/2001/XMLSchema#string

Carlos Suarez

http://www.w3.org/2001/XMLSchema#string

Chris Boshoff

http://www.w3.org/2001/XMLSchema#string

Juan M Funes

http://www.w3.org/2001/XMLSchema#string

Michael Rosu-Myles

http://www.w3.org/2001/XMLSchema#string

Ruth Rubio

http://www.w3.org/2001/XMLSchema#string

P2860

Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection

CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription

NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis

Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45.

FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.

DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.

Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.

Polybrene inhibits human mesenchymal stem cell proliferation during lentiviral transduction

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

P304

2061-2072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/STEM.1472

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Aurora Astudillo-González

Juan Tornin Cavielles

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247772113

http://www.w3.org/2001/XMLSchema#string

P698

23836491

http://www.w3.org/2001/XMLSchema#string